As in the case of systemically administered drugs, there is also a requirement for reliable kinetic evidence for the clinical effectiveness of local therapeutic NSAIDs. The conditions required for this are discussed, and compared with provisions already existing in EC countries. On the basis of a comprehensive review of the literature, it is shown that among all the locally employed NSAIDs, kinetically reliable and plausible evidence of therapeutic effectiveness is, at present, available only for indomethacin, diclofenac, salicylic acid salts and ibuprofen.
Download full-text PDF |
Source |
---|
JACC Case Rep
December 2024
Division of Cardiac Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Sarcomas represent the most common primary cardiac malignancy. A poor prognosis can be improved with multimodal management including aggressive surgical reconstruction in combination with neoadjuvant or adjuvant therapy. We present the case of a primary cardiac sarcoma to describe our approach to a more radical right atrial and bicaval reconstruction.
View Article and Find Full Text PDFJACC Case Rep
December 2024
Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, Florida, USA.
Papillary fibroelastomas (PFEs) are primary cardiac tumors associated with significant embolic risk. Surgical excision or medical therapy with antiplatelets and/or anticoagulants have been the treatment options for symptomatic patients. This paper reports our early experiences of percutaneous removal of PFE using mechanical aspiration techniques.
View Article and Find Full Text PDFJACC Case Rep
December 2024
Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
An 85-year-old woman with atrial fibrillation was found to have a large 4.5- × 3.5-cm left atrial mass.
View Article and Find Full Text PDFClin Transl Sci
January 2025
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
In neurovascular settings, including treatment and prevention of ischemic stroke and prevention of thromboembolic complications after percutaneous neurointerventional procedures, dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care. Clopidogrel remains the most commonly prescribed P2Y12 inhibitor for neurovascular indications. However, patients carrying CYP2C19 no-function alleles have diminished capacity for inhibition of platelet reactivity due to reduced formation of clopidogrel's active metabolite.
View Article and Find Full Text PDFCardiovasc Interv Ther
January 2025
Department of Internal Medicine, Division of Cardiology, Iwate Medical University, 2-1-1 Idaidori, Yahaba-Cho, Shiwa-Gun, Iwate, 028-3695, Japan.
In clinical practice, the impact of procedural or patient-related risk factors on 1-year clinical outcomes in patients receiving 1-month of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy after contemporary percutaneous coronary intervention (PCI) remains unclear. Using data from the multi-center REIWA registry which included patients treated with thin-strut biodegradable polymer drug-eluting stent (BP-DES) and 1-month DAPT followed by P2Y12 inhibitor monotherapy, we assessed the primary endpoint (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, ischemic or hemorrhagic stroke, and major or minor bleeding) in patients with and without procedural (treatment of three vessels, three or more lesions, three or more stents, bifurcation with two stents, long stenting, and target of chronic total occlusion) and patient-related risk factor (renal insufficiency, anemia, peripheral vascular disease, prior or current history of heart failure and advanced age of ≥ 75 years). Among the 1,202 patients who underwent complete revascularization by PCI, 276 (23.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!